Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 2/20 | 0.59 |
| ▸ | IGF1R | P08069 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | RAF1 | P04049 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | AKT1 | P31749 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CNKSR1 | Q969H4 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7365508 | 0.89 | ADORA1 (0.47) | ADORA1IGF1RMAPK1MEN1KMT2A | |
| SCHEMBL7304113 | 0.83 | ADORA1 (0.68) | ADORA1IGF1RMAPK1PDE4BPDE3A | |
| SCHEMBL7291999 | 0.81 | ADORA1 (0.63) | ADORA1IGF1RMAPK1PDE4BPDE3A | |
| SCHEMBL8446408 | 0.80 | ADORA1 (0.59) | ADORA1IGF1RMAPK1PDE4BPDE3A | |
| SCHEMBL7488161 | 0.78 | ADORA1 (0.57) | ADORA1IGF1RMAPK1PDE4BPDE3A | |
| SCHEMBL7299166 | 0.78 | ADORA1 (0.77) | ADORA1IGF1RMAPK1MAPK14MAPK3 | |
| SCHEMBL8810012 | 0.78 | ADORA1 (0.73) | ADORA1IGF1RMAPK1MAPK14MAPK3 | |
| SCHEMBL7301059 | 0.78 | ADORA1 (0.67) | ADORA1IGF1RMAPK1PDE4BPDE3A | |
| SCHEMBL7295203 | 0.78 | ADORA1 (0.73) | ADORA1IGF1RMAPK1PDE4BPDE3A | |
| SCHEMBL19829271 | 0.77 | ADORA1 (0.66) | ADORA1IGF1RMAPK1PDE4BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040152659-A1 | Method for the treatment of parkinson's disease comprising administering an A1A2a receptor dual antagonist | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2004-08-05 | — | — | US | claimed |
| EP-1177797-A9 | NOVEL USE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-05-15 | — | — | EP | claimed |
| EP-1177797-A1 | NOVEL USE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-02-06 | — | — | EP | claimed |
| US-8592420-B2 | Method of treating an anxiety disorder | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2013-11-26 | — | — | US | disclosed |
| US-20120232089-A1 | METHOD OF TREATING AN ANXIETY DISORDER | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-09-13 | — | — | US | disclosed |
| US-8202869-B2 | Method of treating an anxiety disorder | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-06-19 | — | — | US | disclosed |
| US-7759355-B2 | Adenosine A2A receptor antagonists for treating restless legs syndrome or nocturnal myoclonus | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-07-20 | — | — | US | disclosed |
| EP-1534289-B1 | ADENOSINE A2A RECEPTOR ANTAGONISTS FOR TREATING RESTLESS LEGS SYNDROME OR NOCTURNAL MYOCLONUS | KYOWA HAKKO KOGYO KK (JP) | 2008-07-09 | — | — | EP | disclosed |
| US-20070149555-A1 | Prophylatic and/or therapeutic agents for chronic musculoskeletal pain | KYOWA HAKKO KOGYO CO., LTD (JP) | 2007-06-28 | — | — | US | disclosed |
| EP-1738766-A1 | PREVENTIVE AND/OR THERAPEUTIC AGENT FOR DISEASE ACCOMPANIED BY CHRONIC MUSCLE/SKELETON PAIN | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-01-03 | — | — | EP | disclosed |
| US-20060281770-A1 | Method of treating an anxiety disorder | KYOWA HAKKO KOGYO CO. LTD (JP) | 2006-12-14 | — | — | US | disclosed |
| US-20050245545-A1 | Adenosine a2s receptor antagonists for treating restless legs syndrome or related disorders | KYOWA HAKKO KOGYO CO., LTD (JP) | 2005-11-03 | — | — | US | disclosed |
| WO-2004108137-A1 | A METHOD OF TREATING AN ANXIETY DISORDER | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2004-12-16 | — | — | WO | disclosed |
| US-20040152659-A1 | Method for the treatment of parkinson's disease comprising administering an A1A2a receptor dual antagonist | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2004-08-05 | — | — | US | disclosed |
| EP-0925299-B1 | PYRAZOLOPYRIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF | FUJISAWA PHARMACEUTICAL CO (JP) | 2002-09-25 | — | — | EP | disclosed |
| EP-1177797-A9 | NOVEL USE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-05-15 | — | — | EP | disclosed |
| EP-1177797-A1 | NOVEL USE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-02-06 | — | — | EP | disclosed |
| US-6124456-A | Pyrazolopyridine compound and pharmaceutical use thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-09-26 | — | — | US | disclosed |
| EP-0925299-A1 | PYRAZOLOPYRIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-06-30 | — | — | EP | disclosed |
| WO-1998003507-A1 | PYRAZOLOPYRIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152659-A1 | Method for the treatment of parkinson's disease comprising administering an A1A2a receptor dual antagonist | ADORA2A, ADORA1, ADORA2B | ADORA1 2/4885IGF1R 2108/4885MAPK1 1069/4885 |
| US-20050245545-A1 | Adenosine a2s receptor antagonists for treating restless legs syndrome or related disorders | ADORA2A, ADORA2B, ADORA3 | ADORA1 4/4885IGF1R 3704/4885MAPK1 3198/4885 |
| US-20120232089-A1 | METHOD OF TREATING AN ANXIETY DISORDER | ADORA2A, ADORA2B, ADORA3 | ADORA1 4/4885IGF1R 4463/4885MAPK1 4487/4885 |
| US-20060281770-A1 | Method of treating an anxiety disorder | ADORA2A, ADORA2B, ADORA3 | ADORA1 4/4885IGF1R 4463/4885MAPK1 4487/4885 |
| US-20070149555-A1 | Prophylatic and/or therapeutic agents for chronic musculoskeletal pain | ADORA2A, ADORA2B, ADORA3 | ADORA1 5/4885IGF1R 1035/4885MAPK1 1850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.